FAM193A

Across TCGA pan-cancer cohorts, FAM193A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of FAM193A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FAM193A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types FAM193A is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where FAM193A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM193A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	+0.168	<.001	7	view →
LSCC	Male	II,III,IV	−0.157	<.001	6	view →
PDAC	All	All	−0.346	.005	3	view →
LUAD	Male	II,III,IV	−0.139	.044	1	view →
HNSC	All	II,III,IV	−0.121	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

FAM193A–CCRCC

Open the CCRCC breakdown →